10-K/A: TriSalus Life Sciences Reports Reduced 2024 Net Loss and Revenue Growth, But Faces Substantial Going Concern Doubt

TriSalus Life Sciences, an oncology-focused medical technology company, reported a significant reduction in net loss and strong revenue growth for the fiscal year ended December 31, 2024, but disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient liquidity without further financing.

Summary

• TriSalus Life Sciences filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, primarily to correct an audit opinion date and include updated certifications.
• The company reported revenue of $29.43 million for the year ended December 31, 2024, a substantial increase from $18.51 million in 2023.
• Net loss available to common stockholders significantly decreased to $30.05 million in 2024, compared to $59.36 million in 2023.
• Despite the reduced loss, the accumulated deficit grew to $279.5 million as of December 31, 2024, up from $249.5 million in 2023.
• Cash and cash equivalents decreased to $8.53 million as of December 31, 2024, from $11.78 million at the end of 2023.
• Management has raised substantial doubt about the company's ability to continue as a going concern, stating that existing cash and cash equivalents are insufficient to fund projected liquidity requirements for the next 12 months without additional financing.
• The company's core business involves Pressure Enabled Drug Delivery (PEDD) infusion systems, including the TriNav Infusion System, and the investigational immunotherapeutic nelitolimod.
• TriNav received new HCPCS codes (C9797 effective January 1, 2024, and C8004 effective April 1, 2025) from CMS, providing improved reimbursement clarity.
• TriSalus secured a $50.0 million term loan facility from OrbiMed in April 2024, drawing $25.0 million initially and an additional $10.0 million subsequent to December 31, 2024.
• The company raised $14.1 million in 2024 through its Standby Equity Purchase Agreement (SEPA) with Yorkville and an additional $1.0 million from a private placement.
• An exchange offer for warrants in May 2024 led to the conversion of 7,034,639 warrants into 2,110,366 shares of common stock.
• The contingent earnout liability decreased to $7.4 million in 2024 from $18.6 million in 2023, resulting in an $11.2 million gain from fair value remeasurement.

Sentiment

Score: 3

Explanation: While there are positives like revenue growth and reduced net loss, the explicit 'going concern' warning, declining cash balance, and ongoing reliance on external financing for survival indicate a highly precarious financial position. The company's future is heavily dependent on successful capital raises, which are not assured.

Positives

• Revenue increased by approximately 59% to $29.43 million in 2024 from $18.51 million in 2023, indicating strong product adoption and market penetration.
• Net loss available to common stockholders was significantly reduced to $30.05 million in 2024 from $59.36 million in 2023, demonstrating improved financial performance.
• Net cash used in operating activities decreased to $40.84 million in 2024 from $50.58 million in 2023, indicating a more efficient use of cash in core operations.
• The company secured a $50.0 million term loan facility from OrbiMed, with $35.0 million drawn or committed post-year-end, providing substantial capital for operations and strategic plans.
• Successful capital raises through the Standby Equity Purchase Agreement (SEPA) with Yorkville ($14.1 million) and a private placement ($1.0 million) in 2024 diversified funding sources.
• New HCPCS codes (C9797 and C8004) for the TriNav Infusion System, effective January 1, 2024, and April 1, 2025, respectively, enhance reimbursement clarity and market access for the company's technology.
• Research and development expenses decreased to $17.69 million in 2024 from $29.84 million in 2023, potentially reflecting a more focused R&D strategy or completion of certain development phases.
• Total liabilities decreased to $49.87 million in 2024 from $51.66 million in 2023.

Negatives

• The company incurred a net loss of $33.2 million for the year ended December 31, 2024, and has an accumulated deficit of $279.5 million, highlighting a persistent history of unprofitability.
• Cash and cash equivalents declined to $8.53 million as of December 31, 2024, from $11.78 million in 2023, indicating a deteriorating cash position.
• Management explicitly stated 'substantial doubt about its ability to continue as a going concern' due to insufficient cash to fund projected liquidity requirements for the next 12 months without additional financing.
• Sales and marketing expenses increased significantly to $25.84 million in 2024 from $17.03 million in 2023, indicating higher spending in this area without yet achieving profitability.
• Net cash provided by financing activities decreased to $37.94 million in 2024 from $54.63 million in 2023, suggesting a reduced ability to raise capital compared to the prior year, which included significant business combination proceeds.
• The company's current operating plan, even with management's efforts, does not alleviate the substantial doubt about its ability to continue as a going concern.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses and insufficient cash to fund operations for the next 12 months.
• The company has a limited operating history, which makes it challenging to evaluate its long-term prospects and inherent business risks.
• There is a critical need for additional capital, and there is no assurance that such financing can be obtained on satisfactory terms or at all, which could severely impact operations.
• Failure to secure adequate capital could lead to substantial limitations on operations, including hiring freezes, workforce reductions, reduced cash compensation, and deferral of clinical trials and capital expenditures.
• The business operates in a volatile business and technological environment, particularly in the rapidly evolving medical technology and pharmaceutical products and services market.
• The process to test and obtain regulatory approval for nelitolimod is uncertain and may not be successful, impacting future revenue streams.
• The company's evolving business model and the demand for its products pose inherent uncertainties.
• The OrbiMed Credit Agreement includes a subjective acceleration clause, allowing OrbiMed to declare the loan due and payable if a material adverse change in the business occurs.
• Warrants issued by the company may expire worthless, and anti-dilution adjustments could reduce the proceeds received from warrant exercises.
• Utilization of net operating loss (NOL) carryforwards is subject to annual limitations under Section 382 of the Internal Revenue Code, which could result in their expiration before full utilization, increasing future tax liabilities.

Future Outlook

TriSalus Life Sciences aims to fund future operations and execute its long-term business plan, including its transformation into a therapeutics company, by raising additional capital through collaborations, strategic alliances, licensing arrangements, and the issuance of additional equity and/or debt. The company has access to remaining tranches of the OrbiMed Credit Agreement, subject to achieving certain revenue targets, and the Standby Equity Purchase Agreement with Yorkville. However, management explicitly states that their current operating plan does not alleviate the substantial doubt about the company's ability to continue as a going concern, and there is no assurance that adequate capital resources will be available on a timely basis or on satisfactory terms. If not, the company intends to consider limiting operations substantially, including potential workforce reductions, hiring freezes, deferring clinical trials, and reducing other operating costs.

Management Comments

• "Our current operating plan, which is in part determined based on our most recent results and trends, along with the items noted above, causes substantial doubt to exist about our ability to continue as a going concern and managements plans do not alleviate the existence of substantial doubt."
• "Our ability to fund future operations and to continue the execution of our long-term business plan and strategy, including our transformation into a therapeutics company, will require that we raise additional capital through a combination of collaborations, strategic alliances and licensing arrangements, and issuance of additional equity and/or debt."

Industry Context

TriSalus Life Sciences operates in the highly competitive and capital-intensive oncology medical technology and pharmaceutical sectors. The company's focus on Pressure Enabled Drug Delivery (PEDD) systems and the investigational immunotherapeutic nelitolimod positions it within the precision medicine and immuno-oncology trends. The receipt of new HCPCS codes for its TriNav system is a positive development for market access and reimbursement, aligning with industry efforts to secure clear payment pathways for innovative medical devices. However, as an early-stage company with a history of significant losses and a stated 'going concern' risk, TriSalus faces typical challenges of high R&D costs, regulatory hurdles, and the need for continuous capital infusion common in the biotech and medtech startup landscape. Its dual approach of device and drug development is a common strategy to maximize market potential but also increases complexity and capital requirements.

Comparison to Industry Standards

• The company's accumulated deficit of $279.5 million and recurring losses are typical for early-stage biotechnology and medical device companies that are heavily investing in research, development, and commercialization before achieving profitability. Comparable companies in the oncology space, especially those developing novel drug delivery systems or immunotherapies, often experience similar financial profiles in their growth phases.
• The revenue growth from $18.51 million to $29.43 million (a 59% increase) is strong for a medical technology company, indicating increasing adoption of its TriNav system. This growth rate would be considered favorable compared to many mature medical device companies, but it is from a relatively low base.
• The significant R&D expenditure, though reduced in 2024, is consistent with companies pursuing clinical trials and product development, such as those developing new cancer therapies like nelitolimod. For example, many small to mid-cap biotech firms like Mirati Therapeutics (prior to acquisition) or smaller device companies like AngioDynamics also incur substantial R&D costs relative to revenue in their development phases.
• The reliance on external financing, including debt facilities (OrbiMed) and equity raises (SEPA), is standard for companies in this stage, as internal cash flow is insufficient to cover operational and development costs. The 'going concern' warning, while serious, is not uncommon for companies that have not yet reached commercial scale profitability, particularly those with long development cycles for drug candidates.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any legal proceedings and is not aware of any claims or actions pending or threatened against it.

Related Party Transactions

• The Business Combination involved MedTech Acquisition Sponsor LLC (the 'Sponsor') and MTAC's directors and officers, who became Sponsor Holders and are subject to a contingent earnout liability related to their common stock shares.
• The Standby Equity Purchase Agreement (SEPA) is with YA II PN, Ltd. ('Yorkville'), a fund managed by Yorkville Advisors Global, LP, which is a significant financing partner.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future capital raises (common stock sales, warrant exercises, preferred stock conversions). The 'going concern' warning poses a substantial risk to investment value. Sponsor Holders' earnout shares are subject to forfeiture if price targets are not met.
• **Employees**: Potential for workforce reductions, hiring freezes, and reduced cash compensation if the company fails to secure adequate additional capital. However, equity incentive plans (2009 and 2023 Plans, ESPP) are in place to align employee interests with company performance.
• **Customers (Hospitals, Clinics, Physicians)**: Benefit from continued availability of the TriNav Infusion System and improved reimbursement clarity due to new HCPCS codes, potentially increasing adoption and access to the technology.
• **Creditors (OrbiMed)**: The company has significant debt obligations under the OrbiMed Credit Agreement, with interest payments and potential repayment premiums. The subjective acceleration clause in the debt agreement provides OrbiMed with leverage in case of adverse business conditions.
• **Suppliers**: May face delayed payments or reduced orders if the company's liquidity issues worsen and operations are limited.

Next Steps

• Raise additional capital through collaborations, strategic alliances, licensing arrangements, and issuance of additional equity and/or debt to fund future operations and long-term business plan.
• Achieve specified revenue targets to access remaining tranches of the OrbiMed Credit Agreement ($10.0 million and $15.0 million).
• Maintain effectiveness of registration statement and current prospectus for shares issuable upon warrant exercise.
• Continue development and testing of nelitolimod to obtain regulatory approval.
• Manage operating costs and potentially implement limitations such as hiring freezes, workforce reductions, or deferring clinical trials if capital is not secured.
• File definitive proxy statement for 2025 Annual Meeting of Stockholders by April 30, 2025.

Key Dates

Recommendation

Keywords

Oncology, Medical Technology, PEDD, Pressure Enabled Drug Delivery, TriNav, Nelitolimod, TLR9 Agonist, Hepatocellular Carcinoma, Pancreatic Carcinoma, Solid Tumors, Immunotherapeutic, SEC Filing, 10-K/A, Going Concern, Capital Raise, Biotechnology, Pharmaceuticals, Clinical Trials, Reimbursement Codes, OrbiMed, Yorkville, Financial Reporting